Our first product is in the pre-clinical phase.  Successful early studies have established the structural properties of cu-cy nanoparticles, and have found reduced tumor sizes after cu-cy in combination with radiation therapy compared to matching treatments without cu-cy nanoparticles. Liver cancer is a global health challenge with an estimated incidence of >1 million cases worldwide by 2025. Heptatocellular carcinoma (HCC) accounts for ~90% of liver cancer cases. Approximately 80-90% of HCC cases develop in patients with cirrhosis. The overall health status of these patients limits the therapeutic options. In principle, patients with early-stage HCC are candidates for resection, transplantation and local ablation. Patients at intermediate stages are candidates for transarterial chemoembolization (TACE) and advanced patients will first receive systemic therapies. In HCC confined to the liver, prospective studies of stereotactic body radiation therapy show high rates of radiological responses with acceptable radiological safety in predominantly early-stage Child-Pugh A populations. The addition of cu-cy to enhance radiation therapy can potentially decrease the side effects making it a less invasive therapeutic option as compared to resection, transplantation and local ablation. Cu-cy nanoparticles can also extend the usefulness of external beam radiation therapy to later stage patients. In our preliminary experiments, cu-cy enhanced radiation therapy has been shown to work on liver cancer in a mouse model and a rabbit model.